Switch theme
Sign up to access all valuation multiples
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
2008
304
LTM Revenue $337M
LTM EBITDA $35.1M
$351M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Esperion Therapeutics has a last 12-month revenue (LTM) of $337M and a last 12-month EBITDA of $35.1M.
In the most recent fiscal year, Esperion Therapeutics achieved revenue of $332M and an EBITDA of $7.6M.
Esperion Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Esperion Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $337M | XXX | $332M | XXX | XXX | XXX |
| Gross Profit | $267M | XXX | $264M | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 79% | XXX | XXX | XXX |
| EBITDA | $35.1M | XXX | $7.6M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 2% | XXX | XXX | XXX |
| EBIT | $50.1M | XXX | $54.4M | XXX | XXX | XXX |
| EBIT Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | -$44.1M | XXX | -$51.7M | XXX | XXX | XXX |
| Net Margin | -13% | XXX | -16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $148M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Esperion Therapeutics's stock price is $1.
Esperion Therapeutics has current market cap of $168M, and EV of $351M.
See Esperion Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $351M | $168M | XXX | XXX | XXX | XXX | $-0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Esperion Therapeutics has market cap of $168M and EV of $351M.
Esperion Therapeutics's trades at 1.1x EV/Revenue multiple, and 46.4x EV/EBITDA.
Equity research analysts estimate Esperion Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Esperion Therapeutics has a P/E ratio of -3.8x.
See valuation multiples for Esperion Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $168M | XXX | $168M | XXX | XXX | XXX |
| EV (current) | $351M | XXX | $351M | XXX | XXX | XXX |
| EV/Revenue | 1.0x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | 46.4x | XXX | XXX | XXX |
| EV/EBIT | 7.0x | XXX | 6.5x | XXX | XXX | XXX |
| EV/Gross Profit | 1.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.8x | XXX | -3.2x | XXX | XXX | XXX |
| EV/FCF | 3.1x | XXX | -14.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEsperion Therapeutics's last 12 month revenue growth is 0%
Esperion Therapeutics's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.7M for the same period.
Esperion Therapeutics's rule of 40 is -129% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Esperion Therapeutics's rule of X is 11% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Esperion Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Growth | -96% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -129% | XXX | 2% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 11% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 63% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Esperion Therapeutics acquired XXX companies to date.
Last acquisition by Esperion Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Esperion Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Esperion Therapeutics founded? | Esperion Therapeutics was founded in 2008. |
| Where is Esperion Therapeutics headquartered? | Esperion Therapeutics is headquartered in United States of America. |
| How many employees does Esperion Therapeutics have? | As of today, Esperion Therapeutics has 304 employees. |
| Who is the CEO of Esperion Therapeutics? | Esperion Therapeutics's CEO is Mr. Sheldon L. Koenig. |
| Is Esperion Therapeutics publicy listed? | Yes, Esperion Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Esperion Therapeutics? | Esperion Therapeutics trades under ESPR ticker. |
| When did Esperion Therapeutics go public? | Esperion Therapeutics went public in 2013. |
| Who are competitors of Esperion Therapeutics? | Similar companies to Esperion Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Esperion Therapeutics? | Esperion Therapeutics's current market cap is $168M |
| What is the current revenue of Esperion Therapeutics? | Esperion Therapeutics's last 12 months revenue is $337M. |
| What is the current revenue growth of Esperion Therapeutics? | Esperion Therapeutics revenue growth (NTM/LTM) is 0%. |
| What is the current EV/Revenue multiple of Esperion Therapeutics? | Current revenue multiple of Esperion Therapeutics is 1.0x. |
| Is Esperion Therapeutics profitable? | Yes, Esperion Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Esperion Therapeutics? | Esperion Therapeutics's last 12 months EBITDA is $35.1M. |
| What is Esperion Therapeutics's EBITDA margin? | Esperion Therapeutics's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Esperion Therapeutics? | Current EBITDA multiple of Esperion Therapeutics is 10.0x. |
| What is the current FCF of Esperion Therapeutics? | Esperion Therapeutics's last 12 months FCF is $112M. |
| What is Esperion Therapeutics's FCF margin? | Esperion Therapeutics's last 12 months FCF margin is 33%. |
| What is the current EV/FCF multiple of Esperion Therapeutics? | Current FCF multiple of Esperion Therapeutics is 3.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
